Regeneron (REGN)
In a report issued on September 10, Yaron Werber from Cowen & Co. maintained a Hold rating on Regeneron, with a price target of $684.00. The company’s shares closed last Thursday at $557.46.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 22.7% and a 69.6% success rate. Werber covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics.
Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $660.92, which is a 17.8% upside from current levels. In a report issued on September 10, Benchmark Co. also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial
- Regeneron, Sanofi’s Dupixent Shows Sustained Asthma Benefits In 3-Yr Trial
- Regeneron, Roche Team Up To Supply Covid-19 Antibody Cocktail To World
- Regeneron Prices $1.25B Public Offering; Analyst Cautious On Valuation
- Regeneron: Covid-19 Antibody Combo Prevents & Treats Disease In Animals